7种无创诊断模型对慢性乙型肝炎肝纤维化及肝硬化的诊断价值评估

Abstract
Figure/Table
References (31)
Related Citation (15)

Download: PDF (824 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the diagnostic value of liver fibrosis and cirrhosis in patients with chronic hepatitis B (CHB) among the aspartate aminotransferase / platelet ratio (APRI), cirrhosis discriminant score (CDS), and fibrosis index based on the four factors (FIB-4), Forns index, glutamyltransferase / platelet ratio (GPR), King’s score, S index model for chronic. Methods From January 2019 to December 2020, a total of 166 patients with CHB who were admitted to Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and underwent liver biopsy and blood biochemical coagulation tests were selected. According to the liver fibrosis stage (S) of the liver biopsy results, there were 55 cases in the non-obvious liver fibrosis group (S0-1), 97 cases in the significant liver fibrosis group (S2-3), and 14 cases in the early-stage cirrhosis group (S4). The APRI, CDS, FIB-4, Forns index, GPR, King’s score, and S index according to the formula were calculate. At the same time, the receiver operating characteristic (ROC) curves of the above seven models were drawn, and the area under the ROC curve (AUC), sensitivity, and specificity were calculated to evaluate the value of each model in the diagnosis of liver fibrosis. Results Compared with the three groups of model scores, and the difference was highly statistically significant (P ＜ 0.01). Except for the CDS model, each model index was positively correlated with the inflammation grade (r ＞ 0, P ＜ 0.05); the scores of each model were positively correlated with liver fibrosis stage (r ＞ 0, P ＜ 0.05). The AUC of S index, APRI, GPR, and King’s score for the diagnosis of significant liver fibrosis＞0.7. The AUC for the diagnosis of early liver cirrhosis from high to low as GPR, S index, APRI, Forns index, King’s score, CDS, and FIB-4. The AUC analysis of the seven models showed that there was a statistically significant difference between APRI and King’s score in the significant liver fibrosis group (Z = 2.197, P ＜ 0.05); there was no significant difference between the other models (P ＞ 0.05). Conclusion APRI, GPR, King’s score, and S index can better diagnose significant liver fibrosis and early cirrhosis in CHB patients. CDS, FIB-4, Forns index have certain diagnostic value for early liver cirrhosis, but the diagnostic accuracy for significant liver fibrosis is low. APRI and GPR models are simple to calculate, serological indicators are readily available, and the cost is low. It can be recommended as a detection method for liver fibrosis in patients with CHB in the grassroots and areas with limited medical resources, so that some patients can avoid invasive liver biopsy and reduce medical costs.

Key words： Liver fibrosis Liver cirrhosis Chronic hepatitis B Non-invasive diagnostic model

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Xiaoxi WANG Tao DU Shengnan JIANG Yuanye▲ CAO Qin▲

Cite this article:

WU Xiaoxi WANG Tao DU Shengnan JIANG Yuanye▲ CAO Qin▲. Diagnostic value assessment of seven noninvasive diagnostic models in liver fibrosis and cirrhosis of patients with chronic hepatitis B#br#[J]. 中国医药导报, 2022, 19(10): 14-19.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I10/14

[1] World Health Organization. Guidelines for the prevention，care and treatment of persons with chronic hepatitis B infection. Geneva：World Health Organization [EB/OL].http：//www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/.
[2] Marcellin P，Gane E，Buti M，et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B：a 5-year open-label follow-up study [J]. Lancet，2013，381（9865）：468-475.
[3] Bravo AA，Sheth SG，Chopra S. Liver biopsy [J]. N Engl J Med，2001，344：495-500.
[4] Bedossa P，Carrat F. Liver biopsy：the best，not the gold standard [J]. J Hepatol，2009，50（1）：1-3.
[5] Rockey DC，Caldwell SH，Goodman ZD，et al. American Association for the Study of Liver Diseases [J]. Liver Biopsy Hepatology，2009，49：1017-1044.
[6] 王贵强，王福生，庄辉，等.慢性乙型肝炎防治指南（2019年版）[J].临床肝胆病杂志，2019，35（12）：2648-2669.
[7] Resino S，Asensio C，Bellón JM，et al. Diagnostic accuracy of the APRI，FIB-4，and the Forns index for predicting liver fibrosis in HIV/HCV-coinfected patients：a validation study [J]. J Infect，2011，63（5）：402-405.
[8] Zhang W，Sun M，Chen G，et al. Reassessment of gamma-glutamyl transpeptidase to platelet ratio （GPR）：a large-sample，dynamic study based on liver biopsy in a Chinese population with chronic hepatitis B virus （HBV） infection [J]. Gut，2018，67（5）：989-991.
[9] Bonacini M，Hadi G，Govindarajan S，et al. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection [J]. Am J Gastroenterol，1997，92（8）：1302-1304.
[10] Zhou K，Gao CF，Zhao YP，et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B [J]. J Gastroenterol Hepatol，2010，25（9）：1569-1577.
[11] Pang Q，Bi JB，Xu XS，et al. King’s score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma [J]. Eur J Gastroenterol Hepatol，2015，27（11）：1337-1346.
[12] Zeng DW，Dong J，Liu YR，et al. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection [J]. World J Gastroenterol，2016， 22（29）：6663-6672.
[13] Martínez SM，Crespo G，Navasa M，et al. Noninvasive assessment of liver fibrosis [J]. Hepatology，2011，53（1）：325-335.
[14] Wu Z，Dong X，Wang G，et al. China HepB-Related Fibrosis Assessment Research Group. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal [J]. J Viral Hepat，2019，26（2）：287-296.
[15] Liu J，Liang W，Jing W，et al. Countdown to 2030：eliminating hepatitis B disease，China [J]. Bull World Health Organ，2019，97（3）：230-238.
[16] Terrault NA，Lok ASF，Mcmahon BJ，et al. Update onprevention，diagnosis，and treatment of chronic hepatitis B：AASLD 2018 hepatitis B guidance [J]. Hepatology，2018， 67（4）：1560-1599.
[17] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis Bvirus infection [J]. J Hepatol，2017，67（2）：370-398.
[18] Srinivasa Babu A，Wells ML，Teytelboym OM，et al. Elastography in Chronic Liver Disease：Modalities，Techniques，Limitations，and Future Directions [J]. Radiographics，2016，36（7）：1987-2006.
[19] Adams LA，George J，Bugianesi E，et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease [J]. J Gastroenterol Hepatol，2011，26（10）：1536-1543.
[20] Degos F，Perez P，Roche B，et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis：a multicenter prospective study （the FIBROSTIC study） [J]. J Hepatol，2010，53（6）：1013-1021.
[21] Zhang Z，Wang G，Kang K，et al. The Diagnostic Accuracy and Clinical Utility of Three Noninvasive Models for Predicting Liver Fibrosis in Patients with HBV Infection [J]. PLoS One，2016，11（4）：e0152757.
[22] Liu DP，Lu W，Zhang ZQ，et al. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B [J]. J Viral Hepat，2018，25（5）：581-589.
[23] Zhuang Y，Ding H，Zhang Y，et al. Two-dimensional Shear-Wave Elastography Performance in the Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis B：Comparison with Serum Fibrosis Indexes [J]. Radiology，2017，283（3）：873-882.
[24] Kayadibi H，Yasar B，Ozkara S，et al. The diagnostic accuracy of the Forns index，platelet count and AST to Platelet Ratio Index derived fibrosis index for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis [J]. Scand J Clin Lab Invest，2014， 74（3）：240-247.
[25] Wai CT，Greenson JK，Fontana RJ，et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C [J]. Hepatology，2003，38（2）：518-526.
[26] Wu SD，Wang JY，Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model： a comparative study [J]. World J Gastroenterol，2010， 16（4）：501-507.
[27] Jin W，Lin Z，Xin Y，et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis：a leading meta-analysis [J]. BMC Gastroenterol，2012，12：14.
[28] Lemoine M，Shimakawa Y，Nayagam S，et al. The gamma-glutamyl transpeptidase to platelet ratio （GPR） predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa [J]. Gut，2016，65（8）：1369-1376.
[29] Schiavon LL，Narciso-Schiavon JL，Ferraz MLG，et al. The γ-glutamyl transpeptidase to platelet ratio （GPR） in HBV patients：just adding up? [J]. Gut，2017，66（6）：1169-1170.
[30] Toson EA，Shiha GE，El-Mezayen HA，et al. Noninvasive estimation of liver fibrosis in biopsy-proven hepatitis C virus-infected patients：angiogenic fibrogenic link [J]. Eur J Gastroenterol Hepatol，2017，29（2）：199-207.
[31] Cross TJ，Rizzi P，Berry PA，et al. King’s Score：an accurate marker of cirrhosis in chronic hepatitis C [J]. Eur J Gastroenterol Hepatol，2009，21（7）：730-738.